Lara Sullivan resigned as Director at Pyxis Oncology, Inc..
“Also on the Effective Date, Dr. Sullivan resigned from the Board of Directors of the Company.”
Pyxis Oncology, Inc. — fact timeline
Source-grounded facts extracted from Pyxis Oncology, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lara Sullivan departed as Chief Executive Officer at Pyxis Oncology, Inc..
“On April 29, 2026 (the “Effective Date”), the Separation Agreement between the Company and Dr. Sullivan became binding and effective, addressing Dr. Sullivan’s separation from the Company.”
Lara S. Sullivan changed role as Chief Medical Officer at Pyxis Oncology, Inc..
“Lara S. Sullivan, M.D., President and Chief Executive Officer will assume the role of Chief Medical Officer along with her current role as President and Chief Executive Officer.”
Ken Kobayashi departed as Chief Medical Officer at Pyxis Oncology, Inc..
“On March 18, 2025, the Company announced that Ken Kobayashi, M.D., F.A.C.P, is stepping down from his position as the Company's Chief Medical Officer.”
Michael A. Metzger was appointed as Director at Pyxis Oncology, Inc..
“On June 10, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Michael A. Metzger, to its Board of Directors (the “Board”).”
Pyxis Oncology, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 14, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided a corporate update.”
Pyxis Oncology, Inc. reported the full year ended December 31, 2023 results: net income $73.8 million, or ($1.85) per common share.
“Net loss was $73.8 million, or ($1.85) per common share, for the year ended December 31, 2023, compared to $120.7 million, or ($3.65) per common share, for the year ended December 31, 2022.”
Santhosh Palani, Ph.D., CFA was appointed as Director at Pyxis Oncology, Inc..
“On March 12, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Santhosh Palani, Ph.D., CFA ® , to its Board of Directors (the “Board”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.